Abeona Therapeutics Inc.
$5.99
The Read: Abeona Therapeutics’ stock declined about 7% after Q4 2025 earnings as initial ZEVASKYN revenue was minimal despite launch momentum and strong cash, then fell over 10% post-Q1 2026 as early patient treatments and network expansion failed to impress amid a strategic shift away from ophthalmology.
ABEO
Hover to view data
No Data